TY - JOUR
T1 - Effect of drug-induced taurine depletion on cardiac contractility and metabolism
AU - Mozaffari, Mahmood S.
AU - Tan, Boen H.
AU - Lucia, Michael A.
AU - Schaffer, Stephen W.
N1 - Funding Information:
Acknowledgements-The researchw ass upportedb y Grant HL 28445 from the National Instituteso f Health.
PY - 1986/3/15
Y1 - 1986/3/15
N2 - Myocardial taurine content was halved in rats maintained for 3 weeks on tap water containing either 1% guanidinoethylsulfonate (GES) or 3% β-alanine. The decrease in taurine content did not affect myocardial contraction; however, it significantly altered myocardial metabolism. The major effect of the treatment was a significant stimulation in the rate of glycolysis and lactate production. The rise in glycolytic flux was associated with activation of phosphofructokinase, presumably caused by a decrease in tissue citrate levels. GES-treated hearts also contained slightly lower creatine phosphate content, but since this effect was not observed in the β-alanine-treated hearts, it appeared to be independent of taurine depletion. The consequences of these metabolic changes are discussed.
AB - Myocardial taurine content was halved in rats maintained for 3 weeks on tap water containing either 1% guanidinoethylsulfonate (GES) or 3% β-alanine. The decrease in taurine content did not affect myocardial contraction; however, it significantly altered myocardial metabolism. The major effect of the treatment was a significant stimulation in the rate of glycolysis and lactate production. The rise in glycolytic flux was associated with activation of phosphofructokinase, presumably caused by a decrease in tissue citrate levels. GES-treated hearts also contained slightly lower creatine phosphate content, but since this effect was not observed in the β-alanine-treated hearts, it appeared to be independent of taurine depletion. The consequences of these metabolic changes are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0022453483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022453483&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(86)90087-0
DO - 10.1016/0006-2952(86)90087-0
M3 - Article
C2 - 3082336
AN - SCOPUS:0022453483
SN - 0006-2952
VL - 35
SP - 985
EP - 989
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 6
ER -